Pheochromocytomas and Paragangliomas Market Forecast - Unlocking Rare Tumor Insights Through 2034 | DelveInsight

Pheochromocytomas and Paragangliomas (PCPG) are rare neuroendocrine tumors originating from chromaffin cells of the adrenal medulla and extra-adrenal paraganglia, respectively. While pheochromocytomas typically arise in the adrenal glands, paragangliomas can develop anywhere along the sympathetic and parasympathetic chains. Though generally benign, these tumors can secrete excess catecholamines, leading to severe cardiovascular complications such as hypertension, arrhythmias, and even stroke, if not diagnosed and managed promptly.

DelveInsight's comprehensive report, "Pheochromocytomas and Paragangliomas (PCPG) - Market Insights, Epidemiology, and Market Forecast - 2034," offers an in-depth analysis of the PCPG burden, evolving diagnostic landscape, and treatment strategies across the 7MM (the US, EU4 [Germany, France, Italy, Spain], the UK, and Japan). The report provides robust segmentation by disease type (benign vs. malignant), location (adrenal vs. extra-adrenal), and genetic associations (e.g., SDHx mutations), along with historical and projected epidemiological data.

Current PCPG treatment approaches primarily rely on surgical resection, preceded by pharmacological control of catecholamine levels using alpha- and beta-blockers. However, for metastatic or unresectable cases, the therapeutic options are limited, typically involving radiopharmaceuticals like [131I]-MIBG, peptide receptor radionuclide therapy (PRRT), chemotherapy, or newer targeted agents. Given the rare nature of the disease, standardized PCPG treatment protocols are still evolving, and clinical outcomes can vary widely.

The PCPG market is expected to witness modest but meaningful growth through 2034, fueled by rising awareness, improved genetic testing, and advances in imaging and targeted therapies. Emerging research on novel radioligand therapies and small-molecule inhibitors is generating optimism for better outcomes in metastatic or recurrent cases. DelveInsight anticipates increasing interest from niche biotech firms and academic collaborations to address the unmet needs in PCPG therapies, shaping a more targeted and personalized treatment landscape in the coming years.

Request a sample and uncover the latest breakthroughs shaping the pheochromocytomas and paragangliomas market landscape and future outlook @ https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Pheochromocytomas and Paragangliomas Market Report:
• In 2024, the PCPG market size in the 7MM was ~USD 310 million, projected to grow by 2034.
• The U.S. accounted for USD 189 million, expected to rise with new therapy launches.
• There were 5K PCPG incident cases in the 7MM in 2024, expected to increase.
• ~75% of U.S. cases had germline/somatic mutations.
• The EU4 and UK recorded 1.8K incident cases in 2024.
• In May 2025, Merck (NYSE: MRK) announced FDA approval of WELIREG® (belzutifan), an oral HIF-2α inhibitor, for treating adults and children 12+ with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma, rare tumors linked to genetic mutations. Approval was based on the LITESPARK-015 trial demonstrating an objective response rate.
• In January 2025, the FDA accepted for Priority Review an sNDA seeking approval of WELIREG, for the treatment of adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic PCPG. The FDA has set a PDUFA, or target action, date of May 26, 2025
• Emerging therapies for pheochromocytomas and paragangliomas include ONC201, WELIREG (Belzutifan/MK-6482), LUTATHERA (Lutetium [177Lu] oxodotreotide/dotatate), VMT-α-NET, and others.
• Key companies involved in the treatment of pheochromocytomas and paragangliomas include Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.

To know in detail about the pheochromocytomas and paragangliomas market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pheochromocytomas and Paragangliomas Overview
Pheochromocytomas and Paragangliomas are rare neuroendocrine tumors arising from chromaffin cells of the adrenal medulla (pheochromocytomas) or extra-adrenal paraganglia (paragangliomas). These tumors can be either benign or malignant and are often characterized by the excessive secretion of catecholamines, such as adrenaline and noradrenaline, which can lead to life-threatening cardiovascular symptoms, including hypertension, tachycardia, and stroke.

Although most PCPG cases are sporadic, a significant proportion is associated with hereditary syndromes, including mutations in genes like SDHB, VHL, RET, and NF1. Early detection is challenging due to the nonspecific nature of symptoms, but advances in imaging, biochemical testing, and genetic screening have improved diagnosis rates.

Surgical resection remains the mainstay of curative treatment, particularly for localized tumors. In metastatic or unresectable cases, treatment options include radiopharmaceutical therapies (e.g., [131I]-MIBG), peptide receptor radionuclide therapy (PRRT), targeted therapies, and chemotherapy. However, limited therapeutic options and a lack of standardized treatment protocols continue to pose challenges in managing advanced disease.

Ongoing research efforts aim to address these unmet needs by exploring novel targeted therapies, radioligand treatments, and immunotherapy approaches, with the goal of improving long-term outcomes for patients with PCPG.

Get a free sample for the pheochromocytomas and paragangliomas market forecast, size & share analysis report: https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pheochromocytomas and Paragangliomas Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Pheochromocytomas and Paragangliomas Epidemiology Segmentation:
The pheochromocytomas and paragangliomas market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Incident Cases of PCPG
• Occurrence or Absence of mutation in PCPG
• Age-Specific Cases of PCPG
• Stage-Specific Cases of PCPG

Pheochromocytomas and Paragangliomas Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for pheochromocytomas and paragangliomas throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the pheochromocytomas and paragangliomas drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for pheochromocytomas and paragangliomas, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of pheochromocytomas and paragangliomas therapeutics.

Explore how emerging pheochromocytomas and paragangliomas therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pheochromocytomas and Paragangliomas Market Outlook
The treatment landscape for PCPG has remained largely unchanged over the past decades, with surgery as the cornerstone for localized disease and symptomatic therapy (including alpha-blockers, beta-blockers, and catecholamine synthesis inhibitors) playing a critical role in managing functional tumors. In advanced or metastatic PCPG, systemic approaches such as chemotherapy, targeted therapies, Somatostatin Analogs (SSAs), radiometabolic therapy, and loco-regional procedures like cytoreductive surgery, external beam radiotherapy, and radiofrequency ablation are employed, though with variable success.

While DEMSER (metyrosine) remains a decades-old FDA-approved option, and AZEDRA received approval in 2018 for unresectable or metastatic PCPG, the discontinuation of AZEDRA in 2023 due to limited commercial uptake has re-emphasized the urgent need for effective and accessible therapies. The absence of standardized systemic regimens for metastatic disease highlights a critical treatment gap.

Looking ahead, the PCPG market is poised for innovation, with several promising targeted therapies in the pipeline. Ongoing clinical trials are evaluating advanced modalities, including radionuclide therapies with SSTR2 agonists/antagonists and alpha-emitters, cold SSTR2 analogs like LUTATHERA, HIF-2α inhibitors such as WELIREG (belzutifan), and novel agents like ONC201 (a DRD2 and ClpP agonist). These candidates aim to redefine outcomes for patients with advanced or treatment-refractory PCPG.

Despite being a rare indication, the PCPG therapeutic space presents significant opportunities for innovation, with high unmet needs, orphan drug incentives, and increasing clinical interest driving forward momentum.

Pheochromocytomas and Paragangliomas Market Drivers
• The rarity of PCPG, combined with limited approved treatment options, creates a strong demand for novel therapies. This has led to increased interest from pharmaceutical companies, supported by orphan drug designations and regulatory incentives.
• Emerging treatment modalities such as HIF-2α inhibitors (e.g., WELIREG), radioligand therapies (e.g., SSTR2 agonists/antagonists), and precision oncology approaches are transforming the outlook for metastatic PCPG, driving future market growth.

Pheochromocytomas and Paragangliomas Market Barriers
• Due to the ultra-rare nature of PCPG, the market potential remains small, limiting commercial interest, as seen in the discontinuation of AZEDRA due to low demand despite FDA approval.
• There is a lack of widely accepted or effective systemic therapy standards for advanced PCPG, leading to inconsistent treatment practices and hesitation in drug adoption outside clinical trials.

Scope of the Pheochromocytomas and Paragangliomas Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Pheochromocytomas and Paragangliomas Companies: Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.
• Key Pheochromocytomas and Paragangliomas Therapies: ONC201, WELIREG (Belzutifan/MK-6482), LUTATHERA (Lutetium [177Lu] oxodotreotide/dotatate), VMT-α-NET, and others.
• Pheochromocytomas and Paragangliomas Therapeutic Assessment: Pheochromocytomas and Paragangliomas currently marketed, and Pheochromocytomas and Paragangliomas emerging therapies.
• Pheochromocytomas and Paragangliomas Market Dynamics: Pheochromocytomas and Paragangliomas market drivers and Pheochromocytomas and Paragangliomas market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Pheochromocytomas and Paragangliomas Unmet Needs, KOL's views, Analyst's views, Pheochromocytomas and Paragangliomas Market Access and Reimbursement.

To learn more about pheochromocytomas and paragangliomas companies working in the treatment market, visit @ https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Pheochromocytomas and Paragangliomas Market Report Introduction
2. Executive Summary for Pheochromocytomas and Paragangliomas
3. SWOT analysis of Pheochromocytomas and Paragangliomas
4. Pheochromocytomas and Paragangliomas Patient Share (%) Overview at a Glance
5. Pheochromocytomas and Paragangliomas Market Overview at a Glance
6. Pheochromocytomas and Paragangliomas Disease Background and Overview
7. Pheochromocytomas and Paragangliomas Epidemiology and Patient Population
8. Country-Specific Patient Population of Pheochromocytomas and Paragangliomas
9. Pheochromocytomas and Paragangliomas Current Treatment and Medical Practices
10. Pheochromocytomas and Paragangliomas Unmet Needs
11. Pheochromocytomas and Paragangliomas Emerging Therapies
12. Pheochromocytomas and Paragangliomas Market Outlook
13. Country-Wise Pheochromocytomas and Paragangliomas Market Analysis (2020-2034)
14. Pheochromocytomas and Paragangliomas Market Access and Reimbursement of Therapies
15. Pheochromocytomas and Paragangliomas Market Drivers
16. Pheochromocytomas and Paragangliomas Market Barriers
17. Pheochromocytomas and Paragangliomas Appendix
18. Pheochromocytomas and Paragangliomas Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.